HRP20040923A2 - 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy - Google Patents

5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy

Info

Publication number
HRP20040923A2
HRP20040923A2 HRP20040923A HRP20040923A2 HR P20040923 A2 HRP20040923 A2 HR P20040923A2 HR P20040923 A HRP20040923 A HR P20040923A HR P20040923 A2 HRP20040923 A2 HR P20040923A2
Authority
HR
Croatia
Prior art keywords
compound
indicated
trifluoromethylphenyl
cyclopropyl
hydroxy
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Norbert Schmees
Manfred Lehmann
Ulrike Fuhrmann
Peter Muhn
Christa Hegele-Hartung
Michael Klotzbuecher
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02005530A external-priority patent/EP1344776A1/en
Application filed by Schering Ag filed Critical Schering Ag
Publication of HRP20040923A2 publication Critical patent/HRP20040923A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HRP20040923 2002-03-11 2003-03-10 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy HRP20040923A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36304402P 2002-03-11 2002-03-11
EP02005530A EP1344776A1 (en) 2002-03-11 2002-03-11 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
PCT/EP2003/002441 WO2003075915A1 (en) 2002-03-11 2003-03-10 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}- phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy

Publications (1)

Publication Number Publication Date
HRP20040923A2 true HRP20040923A2 (en) 2004-12-31

Family

ID=27806515

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040923 HRP20040923A2 (en) 2002-03-11 2003-03-10 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy

Country Status (26)

Country Link
US (1) US7388006B2 (https=)
EP (1) EP1482925B1 (https=)
JP (1) JP2005526064A (https=)
CN (1) CN1652768A (https=)
AR (1) AR035904A1 (https=)
AU (1) AU2003209720A1 (https=)
BR (1) BR0308394A (https=)
CA (1) CA2478948A1 (https=)
CR (1) CR7490A (https=)
DE (1) DE60311236T2 (https=)
DK (1) DK1482925T3 (https=)
ES (1) ES2280766T3 (https=)
HR (1) HRP20040923A2 (https=)
IL (1) IL164032A0 (https=)
MX (1) MXPA04008881A (https=)
NO (1) NO20044279L (https=)
NZ (1) NZ535427A (https=)
PE (1) PE20040157A1 (https=)
PL (1) PL372490A1 (https=)
PT (1) PT1482925E (https=)
RS (1) RS89504A (https=)
RU (1) RU2314299C2 (https=)
TW (1) TW200307674A (https=)
UA (1) UA78027C2 (https=)
UY (1) UY27715A1 (https=)
WO (1) WO2003075915A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
AU2006324090B2 (en) * 2005-12-09 2012-05-31 F. Hoffmann-La Roche Ag Propionamide compounds as antiinflammatory agents
BRPI0619518A2 (pt) * 2005-12-09 2011-10-11 Hoffmann La Roche moduladores do receptor de glicocorticoide, composição farmacêutica que os compreende e usos dos mesmos
DE102006061913A1 (de) * 2006-12-21 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
CN101289408B (zh) * 2007-04-18 2013-02-27 中国科学院上海药物研究所 非甾体类孕激素受体调节剂及其制备方法、药物组合物和用途
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) * 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2018206521A1 (en) * 2017-05-10 2018-11-15 Ventana Medical Systems, Inc. STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENT
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
NO312255B1 (no) * 2000-06-28 2002-04-15 Pgs Reservoir Consultants As Verktöy for gjennomhulling av et langsgående veggparti av et fôringsrör
DE10038639A1 (de) * 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
WO2002054064A2 (en) * 2000-12-28 2002-07-11 Schering Ag Method for screening for progesterone receptor isoform-specific ligands

Also Published As

Publication number Publication date
UA78027C2 (en) 2007-02-15
US7388006B2 (en) 2008-06-17
MXPA04008881A (es) 2004-12-07
BR0308394A (pt) 2005-01-25
WO2003075915A1 (en) 2003-09-18
TW200307674A (en) 2003-12-16
AR035904A1 (es) 2004-07-28
NZ535427A (en) 2006-08-31
IL164032A0 (en) 2005-12-18
RU2314299C2 (ru) 2008-01-10
AU2003209720A1 (en) 2003-09-22
PL372490A1 (en) 2005-07-25
DK1482925T3 (da) 2007-05-14
PE20040157A1 (es) 2004-06-03
RU2004130430A (ru) 2005-08-10
US20030232824A1 (en) 2003-12-18
CA2478948A1 (en) 2003-09-18
DE60311236D1 (de) 2007-03-08
JP2005526064A (ja) 2005-09-02
CR7490A (es) 2006-02-07
DE60311236T2 (de) 2008-02-14
PT1482925E (pt) 2007-04-30
CN1652768A (zh) 2005-08-10
EP1482925A1 (en) 2004-12-08
NO20044279L (no) 2004-12-08
EP1482925B1 (en) 2007-01-17
ES2280766T3 (es) 2007-09-16
RS89504A (sr) 2006-10-27
UY27715A1 (es) 2003-08-29

Similar Documents

Publication Publication Date Title
HRP20040923A2 (en) 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
Chabbert-Buffet et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
Chwalisz et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis
JP2014532685A (ja) １８−メチル−６，７−メチレン−３−オキソ−１７−プレグナ−４−エン−２１，１７β−カルボラクトン、該化合物を含有する医薬製剤、および子宮内膜症の治療におけるその使用
Cleve et al. Pharmacology and clinical use of sex steroid hormone receptor modulators
US6319912B1 (en) Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
Robbins et al. Mifepristone: clinical pharmacology
Murphy et al. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri
Chwalisz et al. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)
EP1344776A1 (en) 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
Winneker et al. Nonsteroidal progesterone receptor modulators: structure activity relationships
US20030119800A1 (en) Bone anabolic compounds and methods of use
JP2004505929A (ja) ＥＲβ−選択的エストロゲン及びＳＥＲＭ又は抗エストロゲンを有する組合せ製剤
JP4263264B2 (ja) 解離したエストロゲン活性を有する薬剤を製造するための１１位置換ステロイド化合物の用途
Hapangama Mifepristone: the multifaceted antihormone
KR100729311B1 (ko) 호르몬 대체 요법(ｈｒｔ)용 조성물의 성분으로서의메조프로게스틴 (프로게스테론 수용체 조절물질)
Tabata et al. Fungal metabolites, PF1092 compounds and their derivatives, are nonsteroidal and selective progesterone receptor modulators
DE CUPIS et al. NEWVSOLD FASHIONED OESTRADIOL ANTAGONISTS IN MAMMARY CARCINOMA:IN VITRO'ANDIN VIVO'PHARMACOLOGICAL APPROACHES
Anastassakis Progestins
Jensen Estrogens Used in Hormonal Therapy
Ibanez et al. Mechanisms of Action of Sex Steroid Hormones and their Analogs
Qamar et al. Effect of Antiprogestrogen on Myometrial Thickness and Progesterone/Estrogen Receptors in the Rat Myometrium
Ibanez et al. HORMONE ACTION: GENERAL
Marin et al. Selective Estrogen Receptor Modulators. Antonio Cano
Qamar et al. The Effect of Mifepristone Antiprogestrogen on the Number of Progesterone Receptors in the rat Uterus

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070220

Year of fee payment: 5

PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

OBST Application withdrawn